Oncimmune (LON:ONC) Shares Up 14.8% – Here’s What Happened

Oncimmune Holdings plc (LON:ONC) rose 14.8% during mid-day trading on Thursday . The stock traded as high as GBX 1.55 ($0.02) and last traded at GBX 1.55 ($0.02). Approximately 435,299 shares traded hands during trading, a decline of 29% from the average daily volume of 613,270 shares. The stock had previously closed at GBX 1.35 ($0.02).

Oncimmune Trading Up 14.8 %

The stock has a market cap of £1.76 million, a price-to-earnings ratio of 0.17 and a beta of 1.19. The business’s 50 day simple moving average is GBX 9.43 and its 200 day simple moving average is GBX 13.97. The company has a quick ratio of 0.63, a current ratio of 1.14 and a debt-to-equity ratio of -412.06.

Oncimmune (LON:ONC) last issued its earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter. Oncimmune had a net margin of 581.63% and a negative return on equity of 2,277.74%.

About Oncimmune

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.